文献速递基础与转化研究临床试验与 GCP流行病学与生物统计

抗SARS-CoV-2单克隆抗体巴尼韦单抗对COVID-19疫苗接种的内源性免疫应答影响极小

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
PubMed 文献 · Sci Transl Med · 2022-07-27

这项纵向血清学研究评估了在预防研究中先接受COVID-19单克隆抗体的参与者对COVID-19疫苗的内源性抗体应答的幅度和效力。在6个月内,从随机接受巴尼韦单抗或安慰剂的养老院居民和工作人员中采集血清样本,其中一部分参与者后续完成了两剂SpikeVax或Comirnaty mRNA疫苗接种。这项事后分析评估了135名无既往SARS-CoV-2感染参与者的疫苗接种免疫应答,结果显示所有巴尼韦单抗和安慰剂受试者均对完整COVID-19疫苗接种产生了稳健的免疫应答,任何观察到的差异临床重要性不确定。

要点

  • 所有巴尼韦单抗和安慰剂受试者均对完整COVID-19疫苗接种产生稳健免疫应答。
  • 无论年龄、风险类别和疫苗类型,观察到的差异临床重要性不确定。
  • 结果提示尽早接种COVID-19疫苗的获益超过既往预防性单克隆抗体输注对内源性免疫应答的极小影响。

核心结论

  • 所有巴尼韦单抗和安慰剂受试者均对完整COVID-19疫苗接种产生了稳健的免疫应答, irrespective of age, risk category, and vaccine type,任何观察到的差异临床重要性不确定。
  • 结果提示尽早接种COVID-19疫苗的获益超过既往预防性COVID-19单克隆抗体输注对内源性免疫应答的极小影响。

研究设计与样本

  • 这项纵向血清学研究评估了在预防研究中先接受COVID-19单克隆抗体的参与者对COVID-19疫苗的内源性抗体应答的幅度和效力。
  • 在6个月内,从随机接受巴尼韦单抗或安慰剂的养老院居民和工作人员中采集血清样本。
  • 这项试验的非计划组成部分中,一部分参与者后续完成了两剂SpikeVax(Moderna)或Comirnaty(BioNTech/Pfizer)COVID-19 mRNA疫苗的全程接种。
  • 这项事后分析评估了135名无既往SARS-CoV-2感染参与者的疫苗接种免疫应答。

主要发现

  • 所有巴尼韦单抗和安慰剂受试者均对完整COVID-19疫苗接种产生了稳健的免疫应答, irrespective of age, risk category, and vaccine type,任何观察到的差异临床重要性不确定。

关键数值与推荐

  • 使用三种针对巴尼韦单抗不能有效结合的SARS-CoV-2蛋白的检测方法评估抗体滴度和效力,从而反映内源性抗体应答。

临床怎么用

  • 结果提示尽早接种COVID-19疫苗的获益超过既往预防性COVID-19单克隆抗体输注对内源性免疫应答的极小影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of 6 months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines. This post hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Benschop RJ, Tuttle JL, Zhang L, et al. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Sci Transl Med. 2022. PMID: 35679357. doi:10.1126/scitranslmed.abn3041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。